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ABSTRACT
Objective: To investigate multidrug therapy in the
cardiovascular disease (CVD) population and whether it
was associated with suboptimal drug prescribing in
heart failure (HF).
Design: A population-based cross-sectional clinical
data linkage study.
Setting: The clinical database populations were
registered with three general practices in North
Staffordshire that are part of a research network.
Participants: 3155 patients aged 50 years and over
were selected on the basis of a CVD-related prescription
and a CVD consultation code applied to their electronic
medical record in a 2-year time period. All available
diagnostic data were linked to all drugs prescribed data
during this time period. Two study groups were: (1) HF
and (2) non-HF CVD (reference group).
Exposure: A standard drug formulary system was used
to define four multidrug count categories based on the
number of different British National Formulary drug
chapters prescribed at the same time.
Primary and secondary outcome measures:
Optimal HF therapy was defined as the prescribing of
ACE inhibitor (ACEi) or a combination of ACEi and β-
blocker in the 2-year time window. An additional three
specific CVD drug categories that are indicated in HF
were also measured.
Results: The HF group, compared with the reference
group, had higher non-CVD multidrug therapy (26%
with 7 or more counts compared with 14% in the non-
HF CVD reference group). For the first-choice optimal
drug treatment for HF with ACEi (64%) or ACEi and β-
blocker combined therapy (23%), the multidrug-
adjusted associations between the HF group and the
reference group were OR 3.89; 95% CI 2.8 to 5.5 and
1.99; 1.4 to 2.9, respectively. These estimates were not
influenced by adjustment for sociodemographic factors
and multidrug counts.
Conclusions: Multidrug therapy prescribing is much
higher in the HF group than in a comparable CVD group
but did not influence optimal drug prescribing.
BACKGROUND
The prevalence of heart failure (HF) is
increasing in older populations1 and drug
Strengths and limitations of this study
▪ The study has investigated multidrug therapy in
patients with heart failure (HF) drawn from a
large cardiovascular population. The general
practice setting is where most of the patients are
seen and followed-up, and where most of the
drugs are prescribed on a long-term basis. The
cardiovascular group provided an appropriate
comparison for investigating multidrug therapy
and the use of common cardiovascular drugs
such as β-blockers and ACE inhibitor in HF.
Accuracy of recording of morbidity and prescrip-
tion data in the UK general practice has been
found to range from moderate to excellent.42
This study selected patients on the basis of car-
diovascular disease (CVD) prescriptions which
are known to be more accurately and consist-
ently recorded43 and this was linked to consult-
ation data. Furthermore, the general practices
used for this study were all part of the North
Staffordshire Primary Care Research Consortium
which is a network for supporting good-quality
epidemiological data. However, the diagnostic
categories do not convey the other aspect of
measurement, which is severity of HF, which
may influence the levels of prescribing.
▪ The study used recorded data from 2000 to
2001 and the use of ACEi and β-blocker combin-
ation in HF has increased since this time
period.16 So part of the explanations for the low
prescribing of combination therapy could be that
there is often a time lag between the current best
evidence and use in practice. However, the data
provided an appropriate basis for investigating
the a priori hypothesis that multidrug prescrip-
tion influences optimal HF drug prescribing and
we were able to test this on emerging and estab-
lished definitions of optimal therapy.
▪ Multidrug therapy in this study has been defined
by chapter counts in order to characterise more
clearly the scope of non-CVD multidrug therapy
in this group. While this is one epidemiological
perspective, there is still scope for more refined
future definitions that take account of dose and
duration of prescribed drugs.
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therapy is the key therapeutic approach to manage
symptoms and reduce mortality,2 yet mortality, morbidity
and healthcare costs remain high.3 4 Despite strong evi-
dence on the efﬁcacy of speciﬁc cardiovascular drugs in
improving HF outcomes, the underuse of evidence-
based drug therapy persists.5–7 A key challenge in
optimal prescribing is the multiple numbers of other dis-
eases and associated drugs that patients with HF often
experience.8
Older adults are exposed to an increased number of
drug prescriptions and the associated consequence of
potentially inappropriate prescribing.9 This is exacer-
bated in HF where higher levels of comorbidity10 are
associated with an increased number of drugs used in
each patient.11 In HF, however, there are a number of
non-cardiovascular disease (CVD) drugs that are contra-
indicated12 13 and 17% of patients with HF have reported
adverse effects from their multiple drug regimens.14 15
A previous research study showed that comorbidity
strongly inﬂuenced the prescribing of recommended
drug regimens in HF but 44% of patients’ suboptimal
drug regimens were unexplained by comorbidity.16 One
suggestion is that a patient’s multidrug therapy may result
in suboptimal drug prescribing due to the clinical
problem of drug interactions or adverse effects.17
Few studies have characterised the drug regimens in
HF compared with other CVD populations or how multi-
drug therapy affects the prescribing of recommended
CVD drugs in the HF group compared with other
non-HF CVD groups. The aims of the study were (1) to
describe multidrug prescribing in the cardiovascular
general practice population and then (2) to test the
hypothesis that non-CVD multidrug prescribing is asso-
ciated with suboptimal HF drug therapy.
METHODS
Design
This study used a large electronic medical database
linking diagnostic data to all prescribed drugs covering a
2-year time period. Within each study general practice,
diagnostic data and prescribed data were extracted from
the medical records and linked using individual patient
National Health Service (NHS) identiﬁers. The linked
data were then anonymised prior to the data analysis.
The clinical database populations were registered with
one of the three general practices that are part of a
General Practice Research Network. Registered patients
with these three practices had participated in a popula-
tion survey in 2001,18 and a conﬁdential study database
was created which had ethics approval for research.
Study population
The study population was aged 50 years and older and
was from an urban area of England that has a higher
than average number of people with health deprivation
and disability. Ninety-eight per cent of Staffordshire is
Caucasian.19 The three general practices routinely
computer code clinical encounters using the Read code
classiﬁcation20 and drug prescriptions using the British
National Formulary (BNF).21 The Read code classiﬁca-
tion has main chapters on symptoms and diagnostic con-
ditions, and within the main chapter there are four
subhierarchical levels. The BNF has 15 main drug chap-
ters, each related to a different body system, which is
then divided into different subclassiﬁcations of drugs
within the same chapter. Both classiﬁcations provide a
standard coding framework within which diagnostic and
pharmacoepidemiology studies can be investigated in
general practice populations.
From the overall study database, we identiﬁed a study
population of 3155 patients who had received at least
one CVD drug prescription (BNF Chapter 2—‘cardiovas-
cular system’) and one CVD-related consultation code in
the study-deﬁned time period (2000–2001). The data
retrieved from the database also included the patient’s
age, gender and a measure of deprivation. For the
measure of deprivation, we used the Index of Multiple
Deprivation (IMD) score which is a nationally recog-
nised measure of deprivation at the small area level.22
Study groups
Two study groups were constructed on the basis of the
linked diagnostic and prescribed drug information for
the total cardiovascular population of 3155 patients
during the 2-year time window of observation. The
groups were based on CVD diagnostic data, comprising
the HF group and a non-HF CVD group. Patients with
CVD were identiﬁed by the Read code ‘G’ preﬁx
applied on their clinical record. The HF group was iden-
tiﬁed by a range of codes with the preﬁx ‘G58’ which
relates to different HF diagnostic categories, for
example, congestive HF, decompensated HF or left ven-
tricular failure. This group was separated from the
broader cardiovascular group.
Definition of multidrug therapy
There are no standard approaches to deﬁne multidrug
therapy. Previous studies have used the number of pre-
scribed drugs to describe polypharmacy with various
cut-off points deﬁned.23 24 While this approach may be a
useful indication of the level of prescribing in older
adults it is limited in its representation of the range of
different drugs that a patient with multimorbidity may
be exposed to. One method that has been developed in
our previous work,25 and applied in this study sum-
marises the counts of the 15 different system-related
drugs that a person can be prescribed based on the BNF
classiﬁcation. Multidrug is deﬁned as two or more main
drug groups prescribed at the same time. This deﬁnition
provides a proxy measure of the range or spectrum of
multidrug prescribing. Since the main BNF chapter for
CVD was used to select the study population, the other
14 main BNF chapters provided the basis for counting
the number of non-CVD drug groups that a patient had
been prescribed in the 2-year time-window. This
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multidrug measure relates to at least one prescription
for one of the main BNF chapters, and does not include
repeated prescriptions under the same chapter. The
non-CVD drug counts were then categorised into four
count categories: (1) 0 (ie, no non-CVD drugs), (2) 1–3,
(3) 4–6 and (4) 7 or more.
Definition of CVD drug measures
There are a wide range of CVD drugs used in HF, with
some that are recommended in all patients and others
that are indicated depending on the clinical context.
Using the American and European national guidance
for HF,2 26 four CVD drug groups were constructed
(A–D) which represent the potential CVD drugs that
might be prescribed for HF. Category A included the
drugs recommended for all patients who do not have a
clinical contraindication and was subdivided into two
study deﬁnitions of ‘optimal’ HF drug therapy. Groups
B–D included the drugs that are indicated depending
on the clinical context. The four drug groups were
deﬁned as follows:
1. Group A, ‘optimal’ therapy, was deﬁned by (1) the
combined prescribing of ACE inhibitor (ACEi) and
β-blockers; national guidelines recommend the use of
both these CVD drugs as the ﬁrst-choice treatment
for HF with left ventricular systolic dysfunction which
forms the largest part of diagnosed HF2 and (2) the
prescription of at least ACEi over the 2-year study
period. As the evidence on ACEi and β-blocker com-
bination therapy was still being established within the
clinical guidelines at the time of the study inclu-
sion,27 28 the second deﬁnition was created to reﬂect
the established practice at that time. Not all patients
with HF are able to tolerate these drugs, and substitu-
tion by group B drugs may be required, but we
wanted to test the a priori hypothesis that multidrug
therapy inﬂuences the prescription of this recom-
mended ‘ﬁrst-choice’ therapy. Both drugs are also
used more widely in the management of ischaemic
heart disease and hypertension, which may be separ-
ate to or coexist in patients with HF.
2. Group B includes aldosterone antagonists,
angiotensin-11 receptor antagonists and the vasodila-
tor combination, hydralazine and nitrate.29 30 These
drugs are used as an alternative ﬁrst-line treatment in
patients who are intolerant of ACEi or as second-line
treatment in patients who remain symptomatic on
ﬁrst-line treatment using group A drugs.
3. Group C includes Digoxin which is recommended
for symptom reduction31 in patients who remain
symptomatic following prescription of group A and B
drugs as well as for patients with HF with atrial
ﬁbrillation.
4. Group D includes diuretics that are used in all
patients with HF periodically to treat symptoms
related to ﬂuid retention.32 The diuretics group
excluded aldosterone antagonists (spironolactone
and eplerenone) which were classiﬁed in group B.
Statistical analysis
Age of the study population was categorised into four
age bands and the IMD score was categorised into four
quartiles (quartiles 1 (least deprived) to 4 (most
deprived)). There were two stages to the analyses.
First, descriptive data for the study groups and
non-CVD multidrug therapy are presented. The two
study groups are described by age bands, gender and
deprivation quartiles and then non-CVD multidrug pre-
scribing is described for the overall study population by
these study factors and separately for the two study
groups.
Second, the adjusted associations between the HF
group compared with the non-HF CVD group and the
study CVD drug measures are presented. Using logistic
regression methods with 95% CIs, the associations
between the HF group and the four CVD study drug
measures compared with the non-HF CVD reference
group were estimated. OR estimates were adjusted ﬁrst
for age, gender and deprivation quartiles. Next, adjust-
ment was made for non-CVD multidrug counts. This
was ﬁrst conducted by count category and then as a
continuous variable. These steps of adjustment were
performed so that the inﬂuence of non-CVD multi-
drug therapy on the observed associations could be
identiﬁed.
RESULTS
Study population
Of the 3155 study patients, 170 (5.4%) patients were in
the HF group and 2985 (94.6%) were in the reference
group. The HF group was older than the other group.
Forty-four per cent of the HF group was in the oldest
age category compared with 16% of the non-HF CVD
group. Only 3% of the HF group was in the youngest
age category. There were slightly less women than men
in the HF group (48%) but more women than men in
the non-HF CVD group (54%). There was a higher pro-
portion of the HF group with an afﬂuent status (29%)
than the most deprived status (19%; table 1).
Multidrug therapy prescribing
Older age groups had a higher number of multidrug
counts, with 67% of the population aged 80 years and
over being prescribed four or more non-CVD drug
groups, compared with 42% of the population aged 50–
59 years. Women had higher multidrug counts than
men, with 62% being prescribed four or more non-CVD
drug groups compared with just under half of the men.
The most deprived quartile had higher multidrug
counts of 4 or more non-CVD groups than the least
deprived quartile (65% vs 48%, respectively). The HF
group had higher counts of multidrug therapy than the
other CVD group. A quarter (26%) of the HF group
had 7 or more multidrug counts compared with 14% of
the non-HF CVD reference group (table 2).
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Associations between study groups and CVD drugs
More patients with HF were prescribed each of the CVD
drug categories than the reference group. In the HF
group, the most frequent drug therapy prescribed was
diuretics (95%), with 28% for digoxin and 20% for the
antagonist and vasodilator group (table 3). Of the HF
group, 64% were on at least ACEi and 24% were on com-
bined therapy. After adjustment for age, gender and
deprivation, there were signiﬁcant associations between
the HF group and the prescribing of all CVD drug
groups, but the strength of the associations varied. The
strongest associations between the HF group and drug
therapy compared with the reference group were with
diuretics (OR 14.4; 95% CI 7.0 to 29.6). The adjusted
estimate for the association between the HF group and
at least ACEi was 3.99; 95% CI 2.9 to 5.6, and for combined
therapy compared with the reference group was 1.98;
95% CI 1.4 to 2.9. Additional adjustment for non-CVD
multidrug therapy counts did not alter the associations
between HF and any of the related drug groups.
Comparing the HF group with the reference group for
optimal therapy, the multidrug-adjusted associations for
at least ACEi were: HF group—3.89 (2.8 to 5.5) and for
combined therapy were: HF group—OR 1.99 (95% CI 1.4
Table 1 Study population characteristics
Factor Categories
CVD groups
Non-HF CVD (reference)
(n=2985) HF (n=170)
Age 50–59 534 (17.9) 5 (2.9)
60–69 954 (32) 30 (17.6)
70–79 1034 (34.6) 61 (35.9)
80> 463 (15.5) 74 (43.5
Mean age (SD) 69.5 (9.5) 77.0 (8.2)
Gender Women 1623 (54.4) 82 (48.2)
Deprivation quartiles* Q1—least deprived 714 (23.9) 49 (28.8)
Q2 666 (22.3) 45 (26.5)
Q3 782 (26.2 44 (25.9)
Q4—most deprived 822 (27.5) 32 (18.8)
Figures in brackets are the percentage of each factor category within the CVD groups.
All CVD groups are defined by patients who received a British National Formulary Chapter 2 (CVD) drug prescription over a 2-year time
period (2000–2001). Two mutually exclusive groups in the 2-year time period (i)reference group = CVD drug and CVD diagnostic categories
(other than HF) in the record review (ii) HF group = CVD drugs and HF diagnostic categories.
*(n=3154).
CVD, cardiovascular disease; HF, heart failure.
Table 2 Cardiovascular study population and multidrug therapy
Factor Categories
Non-CVD multidrug counts*†
Mean 0 1–3 4–6 7 or more
Total study population 162 (5.1) 1220 (38.7) 1316 (41.7) 457 (14.5)
Age 50–59 4.2 54 (10) 257 (47.2) 187 (34.7) 41 (7.6)
60–69 4.8 62 (6.3) 397 (40.3) 397 (40.3) 128 (13)
70–79 5.2 31 (2.8) 404 (36.9) 483 (44.1) 177 (16.2)
80≥ 5.6 15 (2.8) 162 (30.2) 249 (46.4) 111 (20.7)
Gender Female 5.3 58 (3.4) 594 (34.8) 757 (44.4) 296 (17.4)
Male 4.6 104 (7.2) 626 (43.2) 559 (38.6) 161 (11.1)
Deprivation quartiles† Q1—least deprived 4.6 43 (5.6) 351 (46) 289 (37.9) 80 (10.5)
Q2 4.9 45 (6.3) 273 (38.4) 294 (41.4) 99 (13.9)
Q3 5.0 45 (5.4) 321 (38.9) 346 (41.9) 114 (13.8)
Q4—most deprived 5.5 29 (3.4) 274 (32.1) 387 (45.3) 164 (19.2)
CVD groups non-HF CVD 4.9 161 (5.4) 1176 (39.4) 1235 (41.4) 413 (13.8)
HF 6.1 1 (.6) 44 (25.9) 81 (47.6) 44 (25.9)
Figures in brackets are the percentage of each drug count category within each factor subgroup.
*Non-CVD multidrug counts = number of additional chapters (from 14 possible BNF chapters) from which at least one drug was prescribed
over a 2-year time period (2000–2001).
Both CVD groups are defined by patients who received a British National Formulary Chapter 2 (CVD) drug prescription over a 2-year time
period. Two mutually exclusive groups in the 2-year time-period (1) reference group = CVD drug and CVD diagnostic categories (other than
HF) in the record review (2) HF group = CVD drugs and HF diagnostic categories.
†(n=3154).
BNF, British National Formulary; CVD, cardiovascular disease; HF, heart failure.
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to 2.9; table 3). Adjustment of multidrug counts as a
continuous variable made no difference to the associa-
tions between the HF group and both optimal HF drug
deﬁnitions compared with the reference group—at least
ACEi were: HF group—3.89 (2.8 to 5.5) and combined
therapy were: HF group 2.02 (1.4 to 3.0).
DISCUSSION
In a large cardiovascular general practice population,
our study showed that multidrug prescribing was
common, but did not inﬂuence the association between
the HF group and the prescription of optimal therapy.
The older HF group had the highest non-CVD multi-
drug therapy, yet was still much more likely to receive
cardiovascular drugs than the non-HF CVD group,
which also has other indications for use in general prac-
tice such as hypertension and ischaemic heart disease.
We found that two-thirds of the HF population were
prescribed at least ACEi and a quarter of the HF popula-
tion were prescribed ACEi and β-blockers combined. A
European study found the presence of comorbidity to
account for some but not all of the non-adherence to
the guideline-recommended drug prescribing.16 The
prescribing of high amounts of multiple drugs found in
HF populations may explain the suboptimal prescribing
of HF drug therapy due to contraindications and
adverse effects, but this was found not to be the case in
this study. An additional ﬁnding in the patients with HF
was the higher relative prescribing of diuretics compared
with the other CVD drug groups. Diuretics are used to
control HF symptoms related to ﬂuid retention, such as
breathlessness, but their impact on outcomes such as
mortality is unclear with some studies showing adverse
effects.32 The aim of HF medical treatment is to opti-
mise the mainline drug therapies such as ACEi and
β-blockade and only use diuretics intermittently for
symptom relief. The higher relative prescribing of diure-
tics found in this study potentially represents the trad-
itional drug therapy approach in HF up until the early
1990s when diuretics were the main stay of treatment.33
Studies have shown that the number of drugs that a
patient is prescribed at any one time increases with age
and female gender.34 Our study ﬁndings demonstrate
that this was reﬂected within the general CVD popula-
tion in terms of other multiple drug therapies.
Comparable studies have shown that the average age,
the number of medications and the number of
comorbidities to be high and increasing in the HF popu-
lations.10 35 Our ﬁndings also highlight the increased
multidrug prescribing in the most deprived cardiovascu-
lar populations.
Adherence to evidence-based guidelines for optimal
HF drug therapy by clinicians is poor36 and this adher-
ence is lower in general practice settings than specialist
settings.37 Our ﬁndings found that most patients with
HF were on at least ACEi and a quarter of patients with
HF were prescribed ACEi and β-blockers in combination.
Qualitative studies investigating the clinical reasons for
non-adherence to guidelines include the side effects of
Table 3 Associations between cardiovascular groups and heart failure-related drugs
Study groups
by drug
outcomes
Adjusted OR (95% CI)
Not
prescribed n (%)
Prescribed
n (%)
Unadjusted
OR (95% CI)
Age, gender and
deprivation status*
Age, gender, deprivation
status* and non-CVD
multidrug counts
Group A
At least ACEi
Reference 1971 (66) 1014 (34) 1.0 1.0 1.0
HF 62 (36.5) 108 (63.5) 3.39 (2.5 to 4.7) 3.99 (2.9 to 5.6) 3.89 (2.8 to 5.5)
ACEi and β- blocker combined
Reference 2536 (85.0) 449 (15.0) 1.0 1.0 1.0
HF 131 (77.1) 39 (22.9) 1.68 (1.2 to 2.4) 1.98 (1.4 to 2.9) 1.99 (1.4 to 2.9)
Group B
Reference 2823 (94.6) 162 (5.4) 1.0 1.0 1.0
HF 136 (80.0) 34 (20.0) 4.36 (2.9 to 6.6) 5.06 (3.3 to 7.8) 4.61 (3.0 to 7.1)
Group C
Reference 2830 (94.8) 155 (5.2) 1.0 1.0 1.0
HF 123 (72.4) 47 (27.6) 6.98 (4.8 to 10.1) 4.88 (3.3 to 7.2) 4.75 (3.2 to 7.0)0
Group D
Reference 1265 (42.4) 1720 (57.6) 1.0 1.0 1.0
HF 8 (4.7) 162 (95.3) 14.89 (7.3 to 30.4 14.7 (7.2 to 30.2) 14.4 (7.0 to 29.6)
Both CVD groups are defined by patients who received a BNF Chapter 2 (CVD) drug prescription over a 2-year time period. Two mutually
exclusive groups in the 2-year time period (1)reference group=CVD drug and CVD diagnostic categories (other than HF) in the record review
(2) HF group=CVD drugs and HF diagnostic categories. Heart failure drug groups=groups of HF drugs which at least one drug was prescribed
over a 2-year period; A (optimal therapy)=(a) at least ACEi and (b) ACEi and β-blocker combined, B=aldosterone antagonists, angiotensin II
receptor antagonists or hydralazine/nitrate combination, C=digoxin, D=diuretics.
*(n=3154).
BNF, British National Formulary; CVD, cardiovascular disease; HF, heart failure.
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drugs in patients with HF with comorbidity and multi-
drug therapy,38 39 but our study ﬁndings suggest that the
number and range of non-CVD multidrugs did not inﬂu-
ence the prescribing of HF combination drug therapy.
We deﬁned optimal HF prescribing in this study as the
prescription of recommended ﬁrst-line drug treatments.
Broader deﬁnitions of ‘suboptimal’ therapy include the
‘over-use’ of drugs which expose patients to the risks
associated with polypharmacy and the ‘inappropriate
use’ of drug therapies.9 Older people with multimorbid-
ity are particularly vulnerable to suboptimal prescribing
and one study found over one-third of people aged
70 years or older to be prescribed at least one potentially
inappropriate prescription. This risk increases with the
number of drugs prescribed.40 Our study demonstrates
that older people with HF are exposed to high levels of
non-CVD multidrug counts. While this did not inﬂuence
the prescription of HF ﬁrst-line treatment it has import-
ant clinical implications for the safety and appropriate-
ness of drug regimens for the older patient with HF.
IMPLICATIONS
This study provides population-based evidence on the
multiple drug therapies that patients with HF are
exposed to and the inﬂuence on the prescribing of spe-
ciﬁc HF drug therapy. While multidrug therapy was not
associated with HF prescribing, there is clear scope for
improvements in prescribing within the CVD popula-
tion. Multidrug prescribing and the scale of prescribing
were high in this study and expose patients to potential
adverse effects and inappropriate drug prescribing.
Regular review of drug regimens for patients with HF is
required with particular attention to older age groups,
women and the most deprived populations. Other
studies have found that patients who are prescribed
appropriate drugs for HF often receive suboptimal
dosing,37 39 41 but the inﬂuence of multidrug therapy on
this issue is unclear. Further work is still needed to inves-
tigate the impact of multidrug therapy on optimal
therapy in terms of dose and duration of therapy, and
whether multidrug therapy inﬂuences the prognostic
outcomes in conditions such as HF.
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